Overview

Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex

Status:
Completed

Trial end date:
2020-04-17

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the long term safety and tolerability of diacerein 1% ointment for 2 treatment cycles in subjects with EBS that previously participated in the CCP-020-301 or the CCP-020-101 studies.

Phase:

Phase 2

Details

Lead Sponsor:

Castle Creek Pharmaceuticals, LLC

Treatments:

Diacetylrhein